Technological platforms used for the screening of new antiviral drugs

One of the main characteristics of viruses is their high genetic diversity that generates viral variants with mutations associated with the resistance of antiviral drugs, which leads to therapeutic failure, increases morbidity and mortality and decreases the quality and life expectancy of infected individuals. That is why the need arises to find new alternatives that accept changes in the strongest and most effective devices. Modern pharmacological designs can be made through technological platforms, in a faster, cheaper and more effective way, which offer new promising compounds that act in host-virus binding sites. In this review, we describe the pharmacological objectives and the use of technological tools for the development of new antiviral drugs.